HOME >> BIOLOGY >> NEWS
New Vancomycin Structure May Point To Path For Overcoming Antibiotic Resistance

Towards the end of March, a New York man became the first person in the United States to die from infection by a strain of bacteria resistant to vancomycin, the powerful antibiotic physicians turn to when others fail. The man was only the fourth known case in the world of resistant staphylococcus aureus infection, and government officials are minimizing the danger to public health represented by this first fatality. Still, the death lends urgency to ongoing efforts by researchers to modify vancomycin in ways that will enable the drug to overcome emerging bacterial resistance.

On the heels of this news, scientists at the University of Pennsylvania Medical Center are reporting a significant advance in the search for new and more effective versions of the antibiotic with the discovery of a novel form of vancomycin. The Penn X-ray crystallography results, published in the May issue of Chemistry & Biology, may explain why certain variant molecules synthesized by chemists at Eli Lilly and Co. show marked activity against vancomycin-resistant bacteria. The findings suggest that the two-molecule vancomycin assembly created at Lilly -- referred to as a dimer -- may be configured in a so-called face-to-face orientation of the molecules rather than the back-to-back arrangement thought to be the norm for vancomycin.

"The whole problem of making a drug that works in this context boils down to one molecule of the drug recognizing and binding specifically to another molecule in the cell wall of the bacteria," explains Patrick J. Loll, PhD, an assistant professor of pharmacology and coauthor on the new report. The resistant bacteria have altered the relevant docking molecule so that the normal vancomycin dimer can no longer bind to it, according to Loll.

"The way vancomycin molecules form into dimers or other larger-order complexes may well play a role in how the drug acts," he says. "These findings suggest a hitherto unsuspected way in
'"/>

Contact: Franklin Hoke
hokef@mail.med.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
18-May-1998


Page: 1 2 3

Related biology news :

1. New Drug Shown Effective Against Vancomycin-Resistant Bacteria
2. Researchers Report Emergence Of Antibiotic Resistance During Vancomycin Therapy
3. Structure solved at Scripps shows how one human protein reduces potency of chemotherapy
4. Structure solved by Scripps scientists shows one way that body controls gene expression
5. Structure of a Nobel-prize winning molecule: Aquaporin
6. Structure of HIV-neutralizing antibody solved
7. Structure of key breast cancer receptor determined
8. Structure of cog at the hub of metabolism reveals anti-ageing function
9. Structure of pain-modulating enzyme described by scientists at the Scripps Research Institute
10. Structure reveals details of cells cargo-carriers
11. Structure of key receptor unlocked; Related proteins will fall like dominoes

Post Your Comments:
(Date:5/21/2013)... "place" is increasingly being considered in the management ... new resource that can help them recognize and ... places in their lives. , Place-Based Conservation: ... co-edited by the Pacific Northwest Research Station,s Linda ... to conservation. The book is published by Springer ...
(Date:5/21/2013)... found that a class of pharmaceuticals can both prevent ... drugs, known as "TSPO ligands," are currently used for ... effects of TSPO ligand in young adult mice when ... mice when pathology was quite severe," said lead researcher ... "TSPO ligand reduced measures of pathology and improved behavior ...
(Date:5/21/2013)... of Michigan Water Center today awarded 12 research ... restoration and protection efforts. , The two-year grants ... including efforts to track the remediation of harmful ... control non-native weedy plant invasions; study chromosomal damage ... to restoration activities. , The grants were awarded ...
Breaking Biology News(10 mins):Drugs found to both prevent and treat Alzheimer's disease in mice 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4
(Date:5/22/2013)... Alton Housing Authority was hit by bed bugs. A ... their presence has already caused the company $35,000 for treatment. ... spending, My Cleaning Products shared a way how to ... the report that to clear the infestation , the ... employees also attended a mandatory training on bed bugs, it ...
(Date:5/22/2013)... -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™, ... in vivo production of therapeutic proteins, announced today ... Moderna in early July as its first Chief Information ... in the design and implementation of information systems underlying ... clinical operations and commercial preparedness. John has also been ...
(Date:5/21/2013)... May 21, 2013 Custom Learning ... reporting eLearning solution using Tin Can API combined ... tool. CLD is a leading developer of training ... device companies worldwide. , Tin Can API ... helps learners and trainers more accurately measure the ...
(Date:5/21/2013)... May 21, 2013 The congress ... Transplant Association) is the biggest congress in ... Nearly 10,000 participants are in Istanbul ... research findings. New pioneering studies have been presented: ... PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA USE" ...
Breaking Biology Technology:Bed Bugs Cost Alton Housing Authority $35,000; New Help, How to Kill Bed Bugs With Less Expense, Introduced by My Cleaning Products 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3
Cached News: